EU/3/10/740: Orphan designation for the treatment of multiple myeloma


Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in January 2014 on request of the Sponsor.

On 10 June 2010, orphan designation (EU/3/10/740) was granted by the European Commission to Æterna Zentaris GmbH, Germany, for perifosine for the treatment of multiple myeloma.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Intended use
Treatment of multiple myeloma
Orphan designation status
EU designation number
Date of designation
Æterna Zentaris GmbH
Weismuellerstr. 50
60314 Frankfurt Main
Tel. + 49 6942 6023475
Fax + 49 6942 6023404

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating